Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2024) 99 P235 | DOI: 10.1530/endoabs.99.P235

1Institut Cochin, Paris, France; 2Research Institute, ELPEN, Pikermi, Athens, Greece; 3Human Genetics & Precision Medicine, Heraklion, Greece


The most frequent molecular alteration in adrenocortical tumors (ACT) is the activation of the Wnt/β-catenin pathway that is associated with poor prognosis in adrenocortical carcinoma. Activating β-catenin mutation (p.S31, p.S37, p.S45, T.41) inhibiting its proteosomal degradation by the canonical destruction complex is responsible for its abnormal activation in roughly 30% of ACT. However, the E3 ubiquitin protein ligase 1, SIAH1 is able to ubiquitinate β-catenin even while mutated in intestinal cells, we then, investigate if SIAH1 regulates both wild-type and mutant β-catenin in H295R human adrenocortical cells. We demonstrate that SIAH1 interacts with β-catenin and increases both wild-type and mutant β-catenin ubiquitination through its catalytic RING finger domain. Overexpression of SIAH1 results then, in a decrease in β-catenin half-life (−25%) that is sufficient to reduce β-catenin transcriptional activity (−50%) measured with the TOPFlash reporter even in presence of β-catenin mutation (p.S45) in H295R cells. However, the overexpression of SIAH1 deleted from its catalytic domain does not affect neither β-catenin activity nor its ubiquitination suggesting that the effect of SIAH1 on β-catenin activity depends on its E3 ubiquitin activity. Altogether, our results suggest that SIAH1 indirectly regulates β-catenin transcriptional activity and that promoting SIAH1 activity could limit the activation of this pro-oncogenic pathway while Wnt/β-catenin signaling is constitutively activated.

Volume 99

26th European Congress of Endocrinology

Stockholm, Sweden
11 May 2024 - 14 May 2024

European Society of Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.